CD34 and acute myeloid leukemia: In line with an AML-specific vulnerability, primary human AML cells expressing NUP98::KDM5A and NUP98::NSD1 were 10 times more sensitive to THZ531-mediated CDK12 inhibition than BM mononuclear cells (MNCs) and CD34+ progenitor cells from healthy donors (Fig. 7A).